CompletedPHASE2, PHASE3NCT03473977

Benralizumab for Eosinophilic Gastritis (BEGS)

Studying Primary eosinophilic gastrointestinal disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Children's Hospital Medical Center, Cincinnati
Principal Investigator
Marc E Rothenberg, MD, PhD
Children's Hospital Medical Center, Cincinnati
Intervention
Benralizumab(biological)
Enrollment
26 enrolled
Eligibility
12-60 years · All sexes
Timeline
20182022

Study locations (1)

Collaborators

AstraZeneca

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03473977 on ClinicalTrials.gov

Other trials for Primary eosinophilic gastrointestinal disease

Additional recruiting or active studies for the same condition.

See all trials for Primary eosinophilic gastrointestinal disease

← Back to all trials